Completing data — refresh the page later to see the latest
58-05-9Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2VVIAGPKUTFNRDU-ABLWVSNPSA-N5-formyltetrahydrofolic acid is a formyltetrahydrofolic acid in which the formyl group is located at position 5. It has a role as a mouse metabolite and an Escherichia coli metabolite. It is a conjugate acid of a 5-formyltetrahydrofolate(2-).
58-05-9DTXSID0048216CHEMBL1232801、CHEMBL1679、CHEMBL69905CHEBI:15640>260
245 °C (decomp)
Off-white to light beige amorphous powder. Odorless. Freely soluble in water. Specific optical rotation = +14.9 deg at 21 °C/D ( c= 1 in water). /Calcium salt pentahydrate/
Specific optical rotation = -15.1 deg at 20 °C/D ( c= 1.82) /l-Form calcium salt)
Specific optical rotation = +14.26 deg at 20 °C/D ( c= 3.42 as anhydr Ca salt)
Specific optical rotation: +16.76 deg at 25 °C/D (5% sodium carbonate, concentration = 3.5%).
Leucovorin calcium injection, powder for injection, and tablets should be stored at 15-30 °C and protected from light. /Leucovorin calcium/
When leucovorin calcium powder for injection is reconstituted as directed, resultant solutions should be used immediately when reconstituted with sterile water for injection or within 7 days when reconstituted with bacteriostatic water for injection containing benzyl alcohol. /Leucovorin calcium/
Leucovorin calcium solutions that have been admixed with 10% dextrose injection, 10% dextrose and 0.9% sodium chloride injection, Ringer's injection, or lactated Ringer's injection are stable for 24 hr when stored at room temperature protected from light. Although some former manufacturers of leucovorin calcium powder for injection have recommended that reconstituted solutions of the drug be protected from light, there is evidence that solutions of the drug are not adversely affected by exposure to room light. Reconstituted solutions of leucovorin calcium that have been further diluted with 50 mL of 5% dextrose injection and stored in Viaflex (R) or glass containers unprotected from light retain at least 90% potency for 24 hr at room temperature. /Leucovorin calcium/
pH of saturated aqueous solution 2.8-3.0 at which pH partial decomposition takes place. More stable at neutral or mildly alkaline pH.
196.26 Ų [M-H]- [CCS Type: DT; Method: single field calibrated with Agilent tune mix (Agilent)]
200.58 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
197.5 Ų [M+H]+
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl leucovorin calcium, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Leucovorin Calcium/
SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational exposure or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal, aquatic, and plant life; and conformance with environmental and public health regulations.
Concurrent use of leucovorin /with fluorouracil/ may increase the therapeutic and toxic effects of fluorouracil; although the two medications may be used together for therapeutic advantage, caution is necessary.
Exposure of tumor cells to reduced folates /like leucovorin/ before or with the fluoropyrimidines, 5-fluorouracil or 5-fluoro-2'deoxyuridine, results in a substantial increase in the activity of these drugs. Available evidence suggests that the mechanism of this synergism is a kinetic stabilization of complex formed between thymidylate synthase and fluorodeoxyuridylate that also involves a mole of the cofactor for the thymidylate synthase reaction, 5,10-methylenetetrahydrofolate. This effect results in an extended time of depletion of thymidine nucleotides with a resultant increased level of cell death.
Large dose of leucovorin may counteract the anticonvulsant effects of these medications: /barbiturate anticonvulsants, hydantoin anticonvulsants, primidone/.
The Sprague Dawley rat was used to demonstrate the effect of nitrous oxide, with and without folinic pretreatment, on reproductive indices and fetal development. ... Groups of animals were exposed to 70-75% nitrous oxide on day 9 of pregnancy with or without folinic acid 0.1 mg ip 12 hr before, and immediately before, exposure. Subsequent fetal development was compared with that of various control groups. There were no significant differences in fetal survival, but fetal wt were reduced in both groups exposed to nitrous oxide. Of the indices of skeletal maturity, the number of ossified sternebrae was reduced only in the nitrous oxide group not receiving folinic acid. The incidence of major skeletal abnormalities in the untreated nitrous oxide group was significantly increased to five times that of the control groups, whereas the incidence in the nitrous oxide group receiving folinic acid was not significantly different from control. It is concluded that pretreatment with folinic acid can at least partially reduce the teratogenic effects of nitrous oxide in the rat.
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 1,500(SRC), determined from a structure estimation method(2), indicates that leucovorin is expected to have low mobility in soil(SRC). The pKa values of leucovorin are 3.5 and 4.5 for the carboxylic acids moieties and 10.3 for the amino group(3), indicating that this compound will primarily exist as two anions and one cation in the environment and charged species do not volatilize from moist soil surfaces. Leucovorin is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 2.3X10-21 mm Hg(SRC), determined from a fragment constant method(4). Biodegradation data were not available(SRC, 2005).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 1,500(SRC), determined from a structure estimation method(2), indicates that leucovorin is expected to adsorb to suspended solids and sediment(SRC). The pKa values of leucovorin are 3.1, 4.8 for the carboxylic acid moieties and 10.3 for the amine(3), indicating that this compound will primarily exist as two anions and one cation in the environment and charged species do not volatilize from water surfaces. According to a classification scheme(4), an estimated BCF of 3.2(SRC), from an estimated log Kow of -4.5(5) and a regression derived equation(6) suggests the potential for bioconcentration in aquatic organisms is low(SRC). Biodegradation data were not available(SRC, 2005).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), leucovorin, which has an estimated vapor pressure of 2.3X10-21 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase leucovorin may be removed from the air by wet and dry deposition(SRC). Leucovorin does not absorb UV light >290 nm(3); therefore leucovorin should not be susceptible to photolysis(SRC).
Because folinic acid administration is usually combined with chemotherapy agents, it is challenging to discern causative relationships between folinic acid and adverse effects compared to the chemotherapeutic agents with which they are coadministered. The most commonly reported adverse reactions to folinic acid include GI upset (nausea, vomiting, diarrhea), leukopenia, alopecia, and stomatitis. Other adverse outcomes include erythema, pruritus, skin rash, and urticaria. Although rare, anaphylactic reactions are possible following the administration of folinic acid.
Allergic reactions such as anaphylactoid reactions and urticaria have occurred in patients receiving both oral and parenteral leucovorin.
Therapeutic dosing of folinic acid varies by indication, and there is no internationally accepted single gold-standard regimen.[3] Overdose is rare, and limited data is available about its effects. As mentioned above, folinic acid is commonly used with other chemotherapy agents, and it is challenging to discern causal relationships. Overdose effects generally appear as extensions of the previously mentioned adverse effects.
When administered along with fluorouracil, the following side effects can occur.
As leucovorin is a derivative of folic acid, it can be used to increase levels of folic acid under conditions favoring folic acid inhibition (following treatment of folic acid antagonists such as methotrexate). Leucovorin enhances the activity of fluorouracil by stabilizing the bond of the active metabolite (5-FdUMP) to the enzyme thymidylate synthetase.
The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl leucovorin calcium, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Leucovorin Calcium/
Leucovorin acts as a biochemical modulator and salvage agent that bypasses metabolic blocks in the folate cycle. Its primary action is to restore the pool of reduced folates necessary for DNA and RNA synthesis, thereby preventing or reversing bone marrow suppression and gastrointestinal mucosa inflammation caused by methotrexate. Systemically, it affects rapidly dividing cell populations and can readily cross the blood-brain barrier to concentrate in the cerebrospinal fluid. The drug's duration of action is relatively short. Leucovorin has a wide therapeutic index, though its oral absorption is saturable at doses exceeding 25 mg, necessitating intravenous administration for higher dose requirements. When used with 5-fluorouracil, it significantly enhances the toxicity of the chemotherapy, which may lead to severe diarrhea and dehydration, particularly in elderly or debilitated patients.
Leucovorin is a racemic mixture of diastereoisomers, with the L-isomer (levoleucovorin) being the biologically active moiety. It functions at the molecular level by providing a source of "one-carbon" moieties required for the synthesis of purines and the conversion of deoxyuridylate to thymidylate. Methotrexate acts as a competitive inhibitor of the enzyme DHFR, which normally reduces folic acid to tetrahydrofolate (THF). By providing a pre-reduced form of folate, leucovorin bypasses the DHFR block, allowing for continued DNA synthesis and cellular repair in normal host cells. It also competes with methotrexate for the same active transport processes into the cell, further reducing the drug's toxic impact. In the treatment of colorectal cancer, leucovorin acts as a biochemical sensitizer. 5-FU is metabolized into fluorodeoxyuridylic acid (FdUMP), which binds to the enzyme thymidylate synthase. Leucovorin is converted into 5,10-methylenetetrahydrofolate, which binds to and stabilizes the FdUMP-thymidylate synthase complex. This "ternary complex" locks the enzyme in an inactive state, leading to a more profound inhibition of DNA synthesis and enhanced tumor cell death. In Cerebral Folate Deficiency (CFD), leucovorin serves as a direct substrate to normalize levels of 5-MTHF in the central nervous system, particularly when folate transport across the blood-brain barrier is impaired by autoantibodies or genetic defects.
Leucovorin is a derivative of tetrahydrofolic acid, the reduced form of folic acid, which is involved as a cofactor for 1-carbon transfer reactions in the biosynthesis of purines and pyrimidines of nucleic acids. Impairment of thymidylate synthesis in patients with folic acid deficiency is thought to account for the defective DNA synthesis that leads to megaloblast formation and megaloblastic and macrocytic anemias. Because of its ready conversion to other tetrahydrofolic acid derivatives, leucovorin is a potent antidote for both the hematopoietic and reticuloendothelial toxic effects of folic acid antagonists (eg, methotrexate, pyrimethamine, trimethoprim). It is postulated that in some cancers leucovorin enters and rescues normal cells from the toxic effects of folic acid antagonists, in preference to tumor cells, because of a difference in membrane transport mechanisms; this principle is the basis of high dose methotrexate therapy with leucovorin rescue.
After intravenous administration of leucovorin in adults, the reported mean plasma elimination half-life in the literature was 0.5-1.3 hours for levoleucovorin and 3-7 hours for 5-MTHF.
Terminal half-life for total reduced folates: 6.2 hours.
Following administration of oral leucovorin, levoleucovorin undergoes metabolism in intestinal cells via methenyltetrahydrofolate synthetase (MTHFS) and methylenetetrahydrofolate reductase (MTHFR) to its active metabolite, 5-MTHF. 5-MTHF is the main active metabolite in plasma after oral administration of leucovorin.
In vivo, leucovorin calcium is rapidly and extensively converted to other tetrahydrofolic acid derivatives including 5-methyl tetrahydrofolate, which is the major transport and storage form of folate in the body. /Leucovorin calcium/
Hepatic and intestinal mucosal, mainly to 5-methyltetrahydrofolate (active). After oral administration, leucovorin is substantially (greater than 90%) and rapidly (within 30 minutes) metabolized. Metabolism is less extensive (about 66% after intravenous and 72% after intramuscular administration) and slower with parenteral administration.
Hepatic and intestinal mucosal, the main metabolite being the active 5-methyltetrahydrofolate. Leucovorin is readily converted to another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of fluorodeoxyridylic acid to thymidylate synthase and thereby enhances the inhibition of this enzyme. Half Life: 6.2 hours
Q573I9DVLP
LEUCOVORIN
Established Pharmacologic Class [EPC] - Folate Analog
Chemical Structure [CS] - Folic Acid
Leucovorin is a Folate Analog.
Agents counteracting or neutralizing the action of POISONS.
A group of water-soluble vitamins, some of which are COENZYMES.
Following oral administration of leucovorin in adults, the apparent bioavailability of levoleucovorin is 97% for 25 mg, 75% for 50 mg, and 37% for 100 mg, and dextroleucovorin is approximately 19% for 25 mg, 20% for 50 mg, and 7% for 100 mg. After a single oral 15 mg (7.5 mg/m2) dose of leucovorin, time to peak serum folate concentration is 1.7 hours. As leucovorin is a highly soluble and well absorbed drug, and different immediate-release oral formulations of leucovorin (oral tablet and oral solution) showed relatively higher bioavailability of total folates (>95%), food is not expected to have a clinically significant effect on the pharmacokinetics of leucovorin or 5-MTHF. After intravenous administration of 25 mg in male volunteers, serum total reduced folates reached a mean peak of 1259 ng/mL (range 897 to 1625). The mean time to peak was 10 minutes. After intramuscular injection, the mean peak of serum total reduced folates was 436 ng/mL (range 240 to 725) and occurred at 52 minutes.
Leucovorin is mainly excreted by the kidney as unchanged dextroleucovorin, levoleucovorin, or as 5-MTHF, the metabolic product of levoleucovorin.
Duration of action: All routes: 3 to 6 hours.
Onset of action: Oral: 20 to 30 minutes. Intramuscular: 10 to 20 minutes. Intravenous: Less than 5 minutes.
Crosses blood-brain barrier in moderate amounts; largely concentrated in liver.
Elimination: Renal: 80-90%. Fecal: 5-8%.
Biochemical research.
MEDICATION
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Used in cancer chemotherapy involving the drug methotrexate.
(1) Prepared by catalytic reduction of folic acid, (2) produced microbially.
Manufactoring: Shive, US 2741608 (1956 to Res. Corp.)
Tablets, 5, 10, 15, and 25 mg. Powder for oral solution, 1 mg, following reconstitution. Ampules, 3 mg/ml and 5 mg/ml. Vials, 50, 100, and 350 mg. /Leucovorin calcium/
Oral Tablets, 5 mg (of leucovorin), Wellcovorin (with povidone; scored), Burroughs Wellcome; 10 mg (of leucovorin), Leucovorin Calcium Tablets (scored), Lederle; 15 mg (of leucovorin), Leucovorin Calcium Tablets (scored), Lederle; 25 mg (of leucovorin), Wellcovorin (with povidone; scored), Burroughs Wellcome; Parenteral For Injection, 50 mg (of leucovorin), Leucovorin Calcium for Injection, Cetus, Elkins-Sinn, Lederle; 100 mg (of leucovorin), Leucovorin Calcium for Injection, Cetus, Lederle; Wellcovorin, Burroughs Wellcome; 350 mg (of leucovorin), Leucovorin Calcium for Injection, Lederle; Injection, 3 mg (of leucovorin) per ml, Leucovorin Calcium Injection (with benzyl alcohol 0.9%), Lederle. /Leucovorin calcium/
A member of the folic acid group of vitamins and a growth factor for the bacterium leuconostoc citroforum. Folinic acid is an important metabolite of folic acid and may be the active form in cellular metabolism.
Intermediate product of the metabolism of folic acid; the active form into which that acid is converted in the body, ascorbic acid being a necessary factor in the conversion process.
Information available in 2005 indicated that Leucovorin (folinic acid) was used in the manufacture of pharmaceutical preparations in the following countries: Belgium (1)
Information available in 2005 indicated that Calcium folinate was used in the manufacture of pharmaceutical preparations in the following countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Ireland, Israel, Italy, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russian Federation, Singapore, Slovenia, South Africa, Spain, Sweden, Switzerland, Thailand, Turkey, United Kingdom, United States, Yugoslavia (1,2)
DescriptionFolinic acid, chemical name N-[4-[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridyl) Methyl]amino]benzoyl-L-glutamic acid has been widely used in cancer combined chemotherapy. Folinic acid enters the human body through the ingestion and absorption pathway of folate. Folinic acid (calcium folinate) is a special form of reduced folic acid (folate).
Uses1. It is mainly used as an antidote for folic acid antagonists (such as methotrexate, pyrimethamine or trimethoprim, etc.).2. It is used to prevent severe toxic effects caused by methotrexate overdose or high-dose treatment.3. Megaloblastic anemia caused by folic acid deficiency.4. When combined with fluorouracil, it is used to treat advanced colon cancer and rectal cancer.
UsesAnti-anemic (folate deficiency); antidote (to folic acid antagonists).
UsesFolinic Acid is used in combination with 5-fluorouracil in the treatment of colorectal cancers. It also functions as a useful antidotal therapy medication for decreasing the toxic effect of methotrexate overdosing.
PreparationIn a 1L reaction flask, first add 0.45L of pure water, heat to 55-60℃ with stirring, then add 15g (0.0245mol, water 16.4%) of levofolinate, keep it at 55-60℃, and stir to It is almost dissolved, and the temperature is lowered to 0-10°C first, and an aqueous sodium carbonate solution (2.6g sodium carbonate (0.0245mol) dissolved in 45mL of pure water) is added dropwise, keeping the temperature at 0-10°C, after dripping, keep warm and stir for 1 hour. The precipitated solid is filtered out, the filter cake is washed once with 20 ml of pure water, and the filtrate is the sodium levofolinate solution. Put the filtrate into a 1L reaction flask, stir and lower the temperature to 0-5°C, control the temperature of the reaction system at 0-5°C, and add 1N dilute hydrochloric acid uniformly. When the pH of the acidification end point is 2.0-2.5, stop the dripping. Stir for about 30 minutes, then stand and age for 30 minutes, filter, and wash the filter cake twice with 75 mL of pure water. The wet product is freeze-dried to obtain 9.1 g of Folinic acid. Yield: 78%
DefinitionChEBI: A formyltetrahydrofolic acid in which the formyl group is located at position 5.
For more General Manufacturing Information (Complete) data for LEUCOVORIN (6 total), please visit the HSDB record page.